Palivizumab-resistant human respiratory syncytial virus infection in infancy.
Palivizumab-resistant respiratory syncytial virus was isolated from an infant treated with palivizumab. A stable mutation at codon 276 led to a nearly complete resistance to palivizumab. Additional studies revealed a second mutation at codon 272. Further passage of the virus led to a complete loss of binding of palivizumab.
Adams
Ortwin
O
Institute of Virology, University Children's Hospital, Heinrich-Heine University, Düsseldorf, Germany. ortwin.adams@uni-duesseldorf.de
Bonzel
Linda
L
Kovacevic
Alexander
A
Mayatepek
Ertan
E
Hoehn
Thomas
T
Vogel
Markus
M
D019943:Amino Acid Substitution / Q000235:genetics; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000494:pharmacology*; D004252:DNA Mutational Analysis; D024882:Drug Resistance, Viral; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D020125:Mutation, Missense; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000821:virology*; D018113:Respiratory Syncytial Virus, Human / Q000187:drug effects* / Q000302:isolation & purification
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab